Showing 61–72 of 213 resultsSorted by latest
Pharma & Biotech
CVS posted a strong Q1 performance, revenues reaching $94.6bn making it a 7% growth in revenues from Q1FY24. The adjusted EPS grew from $1.31 in Q1FY24 to $2.25 in Q1FY25.
Biogen’s newly launched drugs i.e. LEQEMBI, ZURZUVAE, SKYCLARYS, and QALSODY collectively generated close to ~$200mn in revenue in Q1 FY25.
Entresto, which is an oral, first-in-class angiotensin receptor-neprilysin inhibitor. Sales of Entresto was $2.3bn up by 50% when compared to Q1FY24.
AMGN has posted double digit sales growth with 14 products mainly with their blockbuster drugs such as Repatha, Evenity and Prolia. Other products also saw a significant growth in sales.
AbbVie is seeing strong progress in its pipeline with new drugs that could support future growth.
AZN secured 13 approvals across key regions and announced five positive Phase III results, including two NMEs.
PFE has maintained its 2025 financial guidance, excluding the potential impact of future trade and tariff policy changes.
Novo showed strong results in Q1FY25, with 18% growth in sales and 20% growth in operating profit
In the MPT segment, sales rose 6% to $1.3bn. Infusion Therapies grew due to strong US demand, and Nutrition sales improved thanks to better supply.
Thermo Fisher Scientific (TMO) reported Q1 revenue of $10.36 billion and adjusted operating income of $2.27 billion, with an adjusted operating margin of 21.9%.
WAT operates in over 35 countries and manufactures in the U.S., Ireland, U.K., and Singapore using global subcontractors.
UNH expected care activity in its Medicare Advantage (MA) business to follow 2024 trends, but in Q1FY25, it rose twice as much as expected, mainly in physician and outpatient care.